Key Insights

Highlights

Treatment Research

7 treatments under study, led by 203lead Pentixather Spectct

Research Leaders

8 sponsors active, led by Holden Comprehensive Cancer Center

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Early Phase 1 (2)
Phase 1 (1)
Phase 2 (1)

Trial Status

Not Yet Recruiting2
Active Not Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06941480Phase 1Not Yet RecruitingPrimary

A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

NCT06148636Early Phase 1Active Not Recruiting

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

NCT05557708Early Phase 1Not Yet Recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

NCT06472388Phase 2Recruiting

Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors

Showing all 4 trials

Research Network

Common Treatments

  • 203lead Pentixather Spectct1
  • Everolimus1
  • 203pb Vmtαnet Spectct1
  • 212lead Pentixather1
  • 177ludtpasc16561

Active Sponsors

  • Holden Comprehensive Cancer Center2
  • National Cancer Institute (NCI)2
  • Perspective Therapeutics1
  • AC Camargo Cancer Center1
  • Yusuf Menda1

Top Investigators

Related Conditions

  • Neuroendocrine Tumor Grade 12
  • Neuroendocrine Tumor Grade 22
  • Neuroendocrine Tumors2
  • Neuroendocrine Tumor Of Pancreas2
  • Neuroendocrine Carcinoma Of Prostate1

Activity Timeline